AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05921201 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Relax, Reflect, and Empower mobile application
Description: Participants in the RRE group will select an Avatar from a pool of 20 Avatars as their companion over the 3 months. The Avatar wellness check-in in the RRE group includes a daily wellness check-in of 5-minute/day (4 days/week), and a weekly full wellness check-in of 15 minutes/week for 3 months. The daily brief check-in includes a wellbeing and mood check and a 3-minute relaxation meditation. The weekly full wellness check-in includes reflection activities in addition to the daily check-in activities.
Study NCT05334914 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Acceptance Commitment Therapy
Description: ACT: Consists of 15 sessions, twice per week. Each session is approximately 2.5 hours including breaks. Clients cover 3 modules (OPEN, ACTIVE, AWARE). Any participant who requires access to a device for any part of the study will be provided with one for the duration of the study.~CM: Participants will be given progressive compensation for session attendance via gift cards or e-gift cards amounting to $520.~Motivation Building Session: The study clinician will meet with each of the participants to explain the process of the therapy, reinforce expectations, and address any concerns or hesitations, and build motivation and commitment to fully engage in the program.~ChillTime App Participants rate their emotional state and choose a coping strategy (either physical, emotional, cognitive or spiritual). The app's algorithm learns the individual's strategy preferences over time, allowing for more personalized suggestions. Participants are also able to access coping strategies ad hoc.
Study NCT06680518 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: tourniquet
Description: peroperation tourniquet
Study NCT06680518 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No tourniquet
Description: no tourniquet during surgery
Study NCT05000723 — intervention group
Intervention type: OTHER
Intervention: Standard of care
Description: Standard of care consisting of~* clearance of infection~* treatment with antibiotics (antisuppressive, DAIR) or surgery (1 stage, 2 stage Girdlestone)~* Radiology: X-ray pelvis and hip, X-ray pelvis with kingmark, CT scan pelvis/hip
Study NCT06250777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg
Study NCT04813640 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Novel spectacles for myopia control
Study NCT04813640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Novel spectacles for myopia control
Study NCT04813640 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacles
Description: Novel spectacles for myopia control
Study NCT06378931 — intervention group
Intervention type: OTHER
Intervention: Quality of life progression after parathyroidectomy
Description: Study the progression of quality of life.
Study NCT05600972 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FSH priming
Description: Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
Study NCT05217680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administration of monthly intravitreal bevacizumab (4-12 injections)
Study NCT05217680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis®
Description: Administration of monthly intravitreal ranibizumab (4-12 injections)
Study NCT05342584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Given PO
Study NCT05342584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV
Study NCT05342584 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study NCT05768217 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resiliency Collective Efficacy Intervention (CRCEI)
Description: The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.
Study NCT05768217 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Sessions
Description: Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
Study NCT05054062 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel node mapping using MRI
Description: Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
Study NCT06279819 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gut microbiota-targeted dietary intervention
Description: The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks.
Study NCT05289830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)
Study NCT05289830 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
Study NCT05337657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB491+Letrozole
Description: Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
Study NCT06359782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor Injection [Cinryze]
Description: C1 Esterase Inhibitor Injection \[Cinryze\]
Study NCT06359782 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
Study NCT06451354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.
Study NCT06451354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).
Study NCT06451354 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
Study NCT06029972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally
Study NCT06029972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally
Study NCT06029972 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study NCT06518928 — intervention group
Intervention type: OTHER
Intervention: Artificial Intelligence assisted sperm selection
Description: SiD software for sperm selection
Study NCT05078957 — intervention group
Intervention type: OTHER
Intervention: Stool sampling
Description: Stool samples will be collected from participants at baseline and annually during 5 years
Study NCT05078957 — intervention group
Intervention type: OTHER
Intervention: Frailty phenotype
Description: According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.
Study NCT05078957 — intervention group
Intervention type: OTHER
Intervention: Blood plasma collection
Description: Blood plasma collection to measure persistent inflammation and immune activation
Study NCT05840302 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
Study NCT05840302 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention
Study NCT05840302 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
Study NCT05840302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
Study NCT04444895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab SC injection
Study NCT04948788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 ；YY-20394
Description: SHR1459 plus YY-20394
Study NCT04948788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Oxaliplatin
Description: Gemcitabine-Oxaliplatin
Study NCT05847855 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for fragmentomic profiles of plasma cell-free DNA
Study NCT06556628 — intervention group
Intervention type: DEVICE
Intervention: Increased Body Temperatures
Description: Collecting data on patients whose body temperatures increase due to fighting an illness.
Study NCT06181578 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ganglionated plexus ablation
Description: This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
Study NCT06209931 — intervention group
Intervention type: PROCEDURE
Intervention: RIRS
Description: RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
Study NCT05159284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Ophthalmic
Description: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MGD Rx EyeBag® eyelid warming device
Description: Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGD Rx EyeBag® eyelid warming device
Description: Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lephanet® lid wipes
Description: Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lephanet® lid wipes
Description: Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%
Description: Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
Study NCT05159284 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%
Description: Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
Study NCT05511194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery therapeutic protocol
Description: Feeding and early ambulation, double short IV antibiotic regimen.
Study NCT05511194 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Conventional management
Description: Delayed feeding and ambulation, triple short IV antibiotic regimen.
Study NCT05447325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)
Description: Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive generic/regular PSAs that address vaping harms more broadly; during the second six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products.
Study NCT05447325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)
Description: Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products; during the second six months, they will receive generic/regular PSAs that address vaping harms more broadly.
Study NCT05447325 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (no message exposure)
Description: Participants will not receive any message intervention in this arm.
Study NCT05903235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Mirror Therapy (VR+MT)
Description: In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.
Study NCT05903235 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Reality-based Mirror Therapy (MR+MT)
Description: In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.
Study NCT05903235 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Mirror Therapy (MT)
Description: In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
Study NCT05312866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia (paracetamol +fentanyl)
Description: Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv
Study NCT05312866 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone
Description: Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
Study NCT04854993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 6 mg/kg
Description: i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB
Study NCT04854993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 4 mg/kg
Description: i.v. injection of a standard dose of sugammadex to reverse dNMB
Study NCT04993131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplant
Description: Liver transplant.
Study NCT06105879 — intervention group
Intervention type: DEVICE
Intervention: covered or open skin
Description: transcutaneous mesarument of covered or open skin area
Study NCT01003561 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia for surgery
Description: spinal anesthesia (T10) for elective TURP surgery
Study NCT04198649 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal treatment and azithromycin treatment
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Drug: two 250mg azithromycin tablets one time daily for 3 days after scaling and root planning sessions
Study NCT04198649 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-surgical periodontal treatment and placebo treatment
Description: Procedure: periodontal treatment: oral hygiene instruction, scaling and root planning Placebo: two 250mg starch tablets one time daily for 3 days after scaling and root planning sessions
Study NCT05616767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on self-screening and HPV vaccination administration
Description: Participants will be taught how to do self-screening for HPV-associated cancers using Training on self-screening and HPV vaccination administration. They will also be given HPV vaccination series.
Study NCT01003028 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil (Limited) - Target Controlled Infusion system
Description: Limit max plasma concentration to 9.8 ng/ml
Study NCT01003028 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil (Control) - Target Controlled Infusion system
Description: Use 20 ng/ml as max plasma concentration
Study NCT06245018 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: iNK Injection
Description: Subjects will receive about 4 cycles of iNK